Regado Biosciences, Inc. (“Regado” or the “Company”), founded in 2003, is a biopharmaceutical company engaged in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The Company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Regado’s paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a “per patient, per setting” basis. Regado’s clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Anticoagulants represent an established multi-billion dollar worldwide market opportunity in need of therapeutics with improved safety and flexibility which optimize therapeutic outcomes. The Company owns or has pending patent protection for worldwide rights to all of its development products, which, for the anticoagulant systems REG1 and REG2, extend through 2025 and beyond. Additionally, Regado has an exciting pipeline of aptamer-control agent pairs against platelet adhesion and/or platelet aggregation targets that recently resulted in the nomination of REG3 as a clinical development candidate. The Company is led by an experienced management team comprising business and scientific leaders with an established track record of successful drug development.